A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.

Trial Profile

A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Simeprevir (Primary) ; Ledipasvir/sofosbuvir; Sofosbuvir
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Janssen Sciences Ireland UC
  • Most Recent Events

    • 17 Apr 2016 Results presented at The International Liver Congress™ 2016
    • 17 Apr 2016 Status changed from recruiting to completed, as per the results presented at The International Liver Congress™ 2016.
    • 11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top